TACC2 (transforming acidic coiled-coil containing protein 2) functions as a centrosomal protein regulating microtubule organization and nuclear-centrosomal coupling 1. While initially characterized in normal postmitotic tissues including brain and muscle 2, TACC2 exhibits context-dependent roles in cancer biology with emerging evidence supporting tumor suppressor functions. In soft tissue sarcoma, TACC2 acts as a tumor suppressor by enhancing transcription of chemokines CCL3 and CCL4, which promote CD8+ T cell infiltration 3. Mechanistically, TACC2 inhibits nuclear translocation of the NuRD/CoREST co-repressor complex, preventing epigenetic repression of immune response genes 3. Similarly, in esophageal squamous cell carcinoma (ESCC), TACC2 loss leads to translocation of NuRD/CoREST components into the nucleus, causing epigenetic repression of CDKN1A (p21) and elevated CDK activation, conferring sensitivity to CDK inhibitors 4. TACC2 inactivation via copy number loss and promoter hypermethylation associates with poor prognosis in ESCC 4. Conversely, TACC2 expression correlates with poor prognosis in breast cancer, associating with higher tumor grade and shorter disease-free survival 2, suggesting tissue-specific oncogenic roles. TACC2 expression is detected in ovarian cancer risk tissues 5. Additionally, rare TACC2 variants were identified in intellectual disability cases 6. These findings establish TACC2 as a multifunctional regulator with context-dependent tumor suppressor or oncogenic roles depending on cancer type and mechanism of inactivation.